<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>North American coral snake (Micrurus fulvius) antivenom: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">North American coral snake (Micrurus fulvius) antivenom: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">North American coral snake (Micrurus fulvius) antivenom: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9766" href="/d/html/9766.html" rel="external">see "North American coral snake (Micrurus fulvius) antivenom: Drug information"</a> and <a class="drug drug_patient" data-topicid="12418" href="/d/html/12418.html" rel="external">see "North American coral snake (Micrurus fulvius) antivenom: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F998742"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antivenin</span></li></ul></div>
<div class="block dop drugH1Div" id="F136139"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Consult with a medical toxicologist or poison control center to determine the appropriate treatment. In patients who are deemed appropriate candidates for antivenom therapy, early use is recommended to prevent the severe and rapidly progressing respiratory depression associated with coral snake envenomation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afd5d66d-2494-48a4-8592-3785c1e440a5">
<i>Micrurus fulvius</i> or <i>Micrurus tener</i> envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Micrurus fulvius</i> (Eastern coral snake) or <i>Micrurus</i>
<i> tener</i> (Texas coral snake) envenomation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 30 to 50 mL (3 to 5 vials) by slow injection; dose dependent on severity of signs/symptoms (smaller children may end up requiring fewer vials); in severe cases, some patients may need more than 10 vials. <b>Note:</b> Each vial of antivenom neutralizes ~2 mg of venom; <i>M. fulvius </i>bites generally deliver ~5 mg of venom (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30773936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30773936'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064896"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51064897"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F136133"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9766" href="/d/html/9766.html" rel="external">see "North American coral snake (Micrurus fulvius) antivenom: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Consult with a medical toxicologist or poison control center to determine the appropriate treatment. In patients who are deemed appropriate candidates for antivenom therapy, early use is recommended to prevent the severe and rapidly progressing respiratory depression associated with coral snake envenomation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6c5d89d7-36c4-4950-a0f3-a6c182bd8821">
<i>Micrurus fulvius</i> or <i>M. tener</i> envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Micrurus fulvius </i></b>
<b>(Eastern coral snake) or</b>
<b>
<i>M. tener </i></b>
<b>(Texas coral snake) envenomation:</b> IV: 30 to 50 mL (3 to 5 vials) by slow injection (dependent on severity of signs/symptoms; some patients may need more than 10 vials).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Each vial of antivenom neutralizes ~2 mg of venom;<i> M. fulvius</i> bites generally deliver ~5 mg of venom (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30773936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30773936'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991913"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989171"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F136116"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate reactions:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate reactions may occur within 30 minutes and may start before needle is withdrawn. Symptoms include apprehension, collapse, cough, cyanosis, dyspnea, facial edema, flushing, laryngeal edema, pruritus, tongue edema, urticaria, vomiting.</p>
<p style="text-indent:-4em;margin-left:6em;">Cardiovascular: Shock</p>
<p style="text-indent:-4em;margin-left:6em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-4em;margin-left:4em;">Delayed reactions:</p>
<p style="text-indent:-2em;margin-left:4em;">Delayed reactions occur 5 to 24 days following administration. Symptoms include arthralgia, edema, fever, lymphadenopathy, malaise, nausea, urticaria, vomiting. Neurological symptoms (eg, amyotrophy, meningism, myasthenia, pain, and peripheral neuritis) may also occur.</p>
<p style="text-indent:-4em;margin-left:6em;">Hypersensitivity: Serum sickness</p></div>
<div class="block coi drugH1Div" id="F136126"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Prophylactic administration in asymptomatic patients; hypersensitivity to horse serum <b>
<i>unless</i></b> the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> There are no absolute contraindications in patients with life- or limb-threatening envenomation.</p></div>
<div class="block war drugH1Div" id="F136114"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate reactions: </i>Patients sensitive to antivenin (<i>M. fulvius</i>) or horse serum may develop anaphylaxis; in addition, patients who have received a prior course of treatment may be at higher risk for a hypersensitivity reaction. Carefully review allergies and history of exposure to products containing horse serum. All patients require close monitoring in a setting that has ready access to emergency medical care.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Delayed reactions: </i>Delayed serum sickness may occur 1 to 3 weeks from administration (especially when large doses used) even with a negative allergic history.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Skin test:</i> The manufacturer states that a skin test may be considered prior to administration in patients sensitive to antivenin (<i>M. fulvius)</i> or horse serum; however, the utility of skin tests to accurately identify patients at risk of early (anaphylactic) or late (serum sickness) hypersensitivity reactions to horse-derived antivenins has been questioned (Chuang 2020; Klaewsongkram 2009; WHO 2005). The absence of a skin hypersensitivity reaction does not exclude anaphylaxis or hypersensitivity following antivenin administration. False-negative rate for skin testing is 10% with similar agents. Conversely, hypersensitivity is not an absolute contraindication in a significantly envenomated patient.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sedatives: Use sedatives with extreme caution; opioids or other analgesics that suppress respiration should not be administered due to the risk of respiratory paralysis following envenomation.</p></div>
<div class="block prod-avail drugH1Div" id="F56619206"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;">The American Association of Poison Control Centers (AAPCC) and the Association of Zoos and Aquariums have developed an online Antivenom Index that is accessible by accredited poison control centers and accredited zoos. Thus, contacting a poison control center can help to locate antivenom sources in emergency situations. It should be noted that dispensation of antivenom is at the discretion of the zoo that possesses said antivenom; a zoo’s decision to provide antivenom may include the costs associated with the desired antivenom and the availability of additional inventory so as not to compromise the safety of their own staff that works with venomous animals.</p>
<p style="text-indent:0em;margin-top:2em;">Cross-neutralization of coral snake (<i>M. fulvius</i>) venom has been demonstrated with Australian ANG Polyvalent Snake Antivenom (CSL Limited, Australia), Coralmyn (Instituto Bioclon, Mexico), and Central American Coral Snake antivenom (<i>Micrurus nigrocinctus</i>) (Instituto Clodomiro Picado, Costa Rica). These should be considered an effective alternative for use in coral snake envenomation in the United States (Arce 2003; McAninch 2019; Ramos 2017; Sanchez 2008; Yang 2017).</p></div>
<div class="block foc drugH1Div" id="F136122"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic:  (1 ea)</p></div>
<div class="block geq drugH1Div" id="F136110"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block admp drugH1Div" id="F52612253"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">Envenomation treatment: IV: <b>Note:</b> Immediate treatment for anaphylactoid and/or hypersensitivity reactions should be available during the infusion. An IV infusion of NS 250 to 500 mL should be started prior to administration of antivenin. Antivenin should be delivered by slow injection or via reservoir bottle. Inject the first 1 to 2 mL of antivenin over 3 to 5 minutes with careful observation for the development of a hypersensitivity reaction. The rate of infusion for the remaining antivenin will be regulated by tolerance to the antivenin, the severity of envenomation, and the maximum safe rate for weight and condition.</p>
<p style="text-indent:-2em;margin-left:4em;">Small children: Allow first 100 mL to infuse rapidly, followed by a decrease in rate to ≤4 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult: Infuse 250 to 500 mL over 30 minutes.</p></div>
<div class="block adm drugH1Div" id="F136124"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Have ready access to medications and equipment for resuscitation. An IV infusion of NS 250 to 500 mL should be started, and the doses of antivenin should be delivered by slow injection or via reservoir bottle. Inject the first 1 to 2 mL of antivenin over 3 to 5 minutes with careful observation for the development of a hypersensitivity reaction. The rate of infusion for the remaining antivenin will be regulated by tolerance to the antivenin, the severity of envenomation, and the maximum safe rate for IV fluids, based on body weight and condition of the patient (eg, 250 to 500 mL over 30 minutes in a previously healthy adult).</p></div>
<div class="block sts drugH1Div" id="F136129"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to reconstitution, store at 2°C to 8°C (36°F to 46°F). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes: </i>Guidelines suggest that at least 5 to 10 vials be stocked in areas with indigenous Eastern coral snakes (<i>M. f. fulvius</i>) or Texas coral snakes (<i>M. f. tener</i>). Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53565477"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of envenomation by an Eastern coral snake (<i>Micrurus fulvius fulvius</i>) or Texas coral snake (<i>Micrurus fulvius</i>
<i> tener</i>) (FDA approved in pediatric patients [age not specified] and adults). <b>Note:</b> Antivenin (<i>Micrurus fulvius</i>) does not neutralize the venom of the Arizona or Sonoran coral snake (<i>Micruroides euryoxanthus</i>) and may not be effective in the management of envenomation from these other species (Ramos 2017).</p></div>
<div class="block cyt drugH1Div" id="F13298766"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F136117"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F13265239"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p>
<p style="text-indent:0em;margin-top:2em;">Available evidence suggests the main adverse pregnancy outcomes associated with a venomous snakebite (eg, fetal loss, placental abruption, preterm labor) are due to the direct effects of the toxin and resulting maternal illness. Antivenom administration in pregnancy should be considered when otherwise clinically indicated using a venom-specific approach, extended fetal and maternal monitoring, supportive care, and treatment of anaphylaxis if needed (Brown 2013).</p></div>
<div class="block mopp drugH1Div" id="F55989411"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Resolution of symptoms of envenomation or emergence of symptoms of immediate hypersensitivity to the antivenin (eg, urticaria, pruritus, erythema, angioedema, bronchospasm with wheezing or cough, stridor, laryngeal edema, hypotension, tachycardia); cardiac monitoring; signs of neurotoxicity (eg, compromised respiratory function/oxygenation); urine for hemoglobinuria.</p>
<p style="text-indent:-2em;margin-left:2em;">Follow-up should be done for all patients for signs and symptoms of delayed allergic reactions or serum sickness (eg, rash, fever, myalgia, arthralgia).</p></div>
<div class="block pha drugH1Div" id="F136113"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Antibodies neutralize the venom components, thereby blocking the effects of the Eastern coral snake (<i>Micrurus fulvius</i>) and Texas coral snake (<i>Micrurus tener</i>) venom.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>In animal models, it has been demonstrated that IV administered coral snake IgG and F(ab’)<sub>2</sub> antivenoms can extravasate blood vessels and slowly neutralize venom absorbed by lymphatics (Paniagua 2019).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Antivenin (<i>Micrurus fulvius</i>) (Equine origin) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12782085">
<a name="12782085"></a>Arce V, Rojas E, Ownby CL, et al. Preclinical assessment of the ability of polyvalent (Crotalinae) and anticoral (Elapidae) antivenoms produced in Costa Rica to neutralize the venoms of North American snakes. <i>Toxicon</i>. 2003;41:851-860. doi:10.1016/s0041-0101(03)00043-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/12782085/pubmed" id="12782085" target="_blank">12782085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140. doi:10.1002/bdra.1000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298218">
<a name="23298218"></a>Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila)</i>. 2013;51(1):3-15. doi:10.3109/15563650.2012.760127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/23298218/pubmed" id="23298218" target="_blank">23298218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31821788">
<a name="31821788"></a>Chuang PC, Chang KW, Cheng FJ, Wu MH, Tsai MT, Li CJ. Risk factors associated with snake antivenom reaction and the role of skin test. <i>Acta Tropica</i>. 2020;203:105293 doi:10.1016/j.actatropica.2019.105293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/31821788/pubmed" id="31821788" target="_blank">31821788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15214622">
<a name="15214622"></a>de Roodt AR, Paniagua-Solis JF, Dolab JA, et al. Effectiveness of Two Common Antivenoms for North, Central, and South American <i>Micrurus</i> Envenomations. <i>J Toxicol Clin Toxicol</i>. 2004;42(2):171-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/15214622/pubmed" id="15214622" target="_blank">15214622</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration (FDA). Information on the Use of Antivenoms. <a href="http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/ucm094321.htm" target="_blank">http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/ucm094321.htm</a>. Last accessed October 31, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18929526">
<a name="18929526"></a>Klaewsongkram J. A role of snake antivenom skin test from the allergist's point of view. <i>Acta Trop</i>. 2009;109(1):84-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/18929526/pubmed" id="18929526" target="_blank">18929526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015;115(5):341-384. doi:10.1016/j.anai.2015.07.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30879857">
<a name="30879857"></a>McAninch SA, Morrissey RP, Rosen P, Meyer TA, Hessel MM, Vohra MH. Snake eyes: coral snake neurotoxicity associated with ocular absorption of venom and successful treatment with exotic antivenom. <i>J Emerg Med</i>. 2019;56:519-522. doi:10.1016/j.jemermed.2019.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/30879857/pubmed" id="30879857" target="_blank">30879857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19673084">
<a name="19673084"></a>Norris RL, Pfalzgraf RR, Laing G. Death Following Coral Snake Bite in the United States-First Documented Case (With ELISA Confirmation of Envenomation) in Over 40 Years. <i>Toxicon</i>. 2009;53(6):693-697.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/19673084/pubmed" id="19673084" target="_blank">19673084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30773936">
<a name="30773936"></a>Paniagua D, Vergara I, Román R, et al. Antivenom effect on lymphatic absorption and pharmacokinetics of coral snake venom using a large animal model. <i>Clin Toxicol (Phila)</i>. 2019;57(8):727-734. doi:10.1080/15563650.2018.1550199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/30773936/pubmed" id="30773936" target="_blank">30773936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27595162">
<a name="27595162"></a>Ramos HR, Vassão RC, de Roodt AR, et al. Cross neutralization of coral snake venoms by commercial Australian snake antivenoms. <i>Clin Toxicol (Phila</i>). 2017;55(1):33-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/27595162/pubmed" id="27595162" target="_blank">27595162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18054059">
<a name="18054059"></a>Sanchez EE, Lopez-Johnston JC, Rodriguez-Acosta A, et al. Neutralization of two North American Coral Snake venoms with United States and Mexican antivenoms. <i>Toxicon</i>. 2008;51(2):297-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/18054059/pubmed" id="18054059" target="_blank">18054059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20231886">
<a name="20231886"></a>Tanaka GD, Furtado Mde F, Portaro FC, et al. Diversity of Micrurus Snake Species Related to Their Venom Toxic Effects and the Prospective of Antivenom Neutralization. <i>PLoS Negl Trop Dis</i>. 2010;4(3):e622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/20231886/pubmed" id="20231886" target="_blank">20231886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20070180">
<a name="20070180"></a>Walter FG, Stolz U, Shirazi F, et al. Temporal Analyses of Coral Snakebite Severity Published in the American Association of Poison Control Centers’ Annual Reports from 1983-2007. <i>Clin Toxicol (Phila)</i>. 2010;48(1):72-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/20070180/pubmed" id="20070180" target="_blank">20070180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23962099">
<a name="23962099"></a>Wood A, Schauben J, Thundiyil J, et al. Review of eastern coral snake (<i>Micrurus fulvius fulvius</i>) exposures managed by the Florida Poison Information Center Network: 1998-2010. <i>Clin Toxicol (Phila)</i>. 2013;51(8):783-788.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/23962099/pubmed" id="23962099" target="_blank">23962099</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guidelines for the clinical management of snake bites in the South-East Asia region. https://apps.who.int/iris/bitstream/handle/10665/205171/B0241.pdf;jsessionid=4D05C9A5C3710A16F0208621984B78DC?sequence=1. Published 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28674788">
<a name="28674788"></a>Yang DC, Dobson J, Chochran C, et al. The bold and the beautiful: a neurotoxicity comparison of new world coral snakes in the <i>Micruroides</i> and <i>Micrurus </i>genera and relative neutralization by antivenom. <i>Neurotox Res.</i> 2017;32:487-495. doi:10.1007/s12640-017-9771-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-pediatric-drug-information/abstract-text/28674788/pubmed" id="28674788" target="_blank">28674788</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 132207 Version 11.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
